The Greater Cannabis Company, Inc. (GCAN)
OTCMKTS · Delayed Price · Currency is USD
0.0700
0.00 (0.00%)
At close: Jan 21, 2026
GCAN Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
1
Market Cap
66.15K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 12.63K | -35.41K | -73.71% |
| Dec 31, 2020 | 48.04K | 40.92K | 574.78% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Amexdrug | 9.17M |
| Acura Pharmaceuticals | 1.56M |
| For The Earth | 687.89K |
| Hemp, Inc | 184.40K |
| Pineapple Express Cannabis Company | 4.33K |
The Greater Cannabis Company News
- 7 weeks ago - GCANRx Announces Relisting To OTCQB Market Tier - GlobeNewsWire
- 7 months ago - GCANRx Announces Uplisting to New Market Tier - GlobeNewsWire
- 1 year ago - GCAN to Explore Strategic Alternatives in Artificial Intelligence and Quantum Computing - GlobeNewsWire
- 2 years ago - GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy - GlobeNewsWire
- 2 years ago - GCANRx Featured in American Journal of Endocannabinoid Medicine - GlobeNewsWire
- 2 years ago - GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders - GlobeNewsWire
- 3 years ago - GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders - GlobeNewsWire
- 4 years ago - GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special - GlobeNewsWire